Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Month: February 2019

When “liking” your favorite tweet isn’t enough, you can now send small bitcoin transactions.

Announced Saturday, the beta app Tippin has released a new Chrome Extension available to Google browser users. Over Twitter, app users can send bitcoin payments via the Lightning Network, considered a way to make bitcoin transactions feasible at a large scale for the first time.

With the extension enabled, a little lightning bolt symbol pops up inside every tweet next to the more familiar “like” and “retweet” buttons.

Read more

Officials in Tokyo are testing a new technology that utilizes weather radar and terrestrial digital radio waves to “quickly and precisely predict torrential rain and tornadoes” up to 20 to 30 minutes in advance, the Mainichi reported on Sunday.

The new technology is being developed by “industry, government and academic bodies including the National Institute of Information and Communications Technology (NICT)” based in Koganei, the Mainichi wrote, and is hoped to be ready for deployment ahead of the 2020 Tokyo Olympics and Paralympics. Existing radar systems are limited in their ability to predict “guerilla rainstorms,” so called because they form quickly from rising, cooling water vapor and strike with little warning in specific areas. However, the new system is much more powerful and capable of estimating the size of raindrops and the structure of clouds, the Mainichi wrote:

Developers say the new “multi parameter phased array weather radar” (MP-PAWR) being tested can predict torrential downpours and tornadoes 20 to 30 minutes before they occur. This is because it has a flat antenna that emits radio waves over a wider range than the rotating bowl-shaped antennas used in traditional radars. It is a combination of an MP radar that enables observation of the size of raindrops, and a phased array radar that provides 3D scans of the structure of clouds in about 30 seconds.

Read more

The Longevity Therapeutics Summit was focused on therapeutics that target aging, rather than basic research or theory.

This was the first year for the Longevity Therapeutics Summit in San Francisco, California. Ably organized by Hanson Wade, with John Lewis, CEO of Oisín Biotechnologies, as program chair, the conference focused on senolytics for senescent cell clearance, big data and AI in finding new drugs (“in silico” testing), delivery systems for therapeutics like senolytics, TORC1 drugs, and biomarkers of aging, and the challenges of clinical trial development and FDA approval.

The conference featured a smorgasbord of cutting-edge longevity research, and, as the name implies, the general focus was on therapeutics that target aging, rather than basic research or theory.

Ned David, CEO of Unity Biotechnology, kicked off the conference with a talk about the company’s latest research on senolytics, which clear away senescent (“zombie”) cells, which secrete harmful chemicals that can cause neighboring cells to also become senescent. Unity has made the news recently with an extension request for its clinical trial of its first-in-class senolytics for osteoarthritis. Its preliminary Phase 1 clinical trial results were deemed “safe,” a major step in obtaining FDA approval, and the full results will be available later this year or in 2020.

Read more

Plants are master chemists, and Michigan State University researchers have unlocked their secret of producing specialized metabolites.

The research, published in the latest issue of Proceedings of the National Academy of Sciences, combined plant biology and machine learning to sort through tens of thousands of genes to determine which genes make specialized metabolites.

Some metabolites attract pollinators while others repel pests. Ever wonder why deer eat tulips and not daffodils? It’s because daffodils have metabolites to fend off the critters who’d dine on them.

Read more

An MIT-led research team has developed a drug capsule that could be used to deliver oral doses of insulin, potentially replacing the injections that people with type 1 diabetes have to give themselves every day. About the size of a blueberry, the capsule contains a small needle made of compressed insulin, which is injected after the capsule reaches the stomach. In tests in animals, the researchers showed that they could deliver enough insulin to lower blood sugar to levels comparable to those produced by injections given through skin. They also demonstrated that the device can be adapted to deliver other protein drugs.

Capsule that releases insulin in the stomach could replace injections for patients with type 1 diabetes.

Read more

In the life-threatening condition known as sepsis, the body responds to infection by inducing widespread biochemical changes that make the situation worse, some of which can lead to a severe decline in blood pressure. Several molecular factors that alter the constriction of blood vessels are involved in this decline, including nitric oxide, prostaglandins and oxidants such as hydrogen peroxide. In 2010, kynurenine — a metabolic product of the amino acid tryptophan — was identified as another factor that causes blood vessels to widen during sepsis. Writing in Nature, Stanley et al. (who work in the same laboratory as the researchers who identified kynurenine) now say that they got the wrong culprit.

Nine years ago, the compound kynurenine was reported to be responsible for the dilation of blood vessels during a potentially fatal inflammatory condition. New evidence has now identified the true culprit. A re-evaluation of a factor involved in vasodilation.

Read more